TBPH - Theravance Biopharma, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
28.59
-0.54 (-1.85%)
As of 3:28PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close29.13
Open29.26
Bid28.50 x 800
Ask28.57 x 1100
Day's Range27.99 - 29.40
52 Week Range21.27 - 35.48
Volume217,092
Avg. Volume243,089
Market Cap1.575B
Beta (3Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-4.89
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.88
Trade prices are not sourced from all markets
  • PR Newswire7 hours ago

    Theravance Biopharma Reports Data from TD-1473 Phase 1b Four-Week Study in Oral Late-Breaker Presentation at UEG Week 2018

    DUBLIN, Oct. 22, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today reported the results from the exploratory Phase 1b study of the gut-selective pan-Janus kinase (JAK) inhibitor TD-1473 in an oral presentation as part of the late-breaker session at United European Gastroenterology (UEG) Week 2018. Presented data demonstrated that four weeks of TD-1473 treatment led to signals of biological activity and localized target engagement with low systemic exposures and no evidence of systemic immunosuppression or opportunistic infections in patients with moderately to severely active ulcerative colitis.

  • See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Theravance Biopharma Inc.

    Short interest is moderately high for TBPH with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners
    American City Business Journals7 days ago

    Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners

    A look at who's moving, who's growing and who's dealing in the Bay Area's health care and life sciences space.

  • PR Newswire11 days ago

    Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data from multiple studies of YUPELRI™ (revefenacin) inhalation solution were presented at the 2018 CHEST annual meeting, which was held in San Antonio, Texas on October 6-10, 2018. The Prescription Drug User Fee Act (PDUFA) date for YUPELRI is November 13, 2018. If approved, YUPELRI would be the first and only once-daily, long-acting nebulized bronchodilator for the treatment of COPD. YUPELRI is designed to be compatible with any standard jet nebulizer.

  • PR Newswire12 days ago

    Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018

    DUBLIN, Oct. 10, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that the results from the Phase 1b study of TD-1473 in patients with moderately-to-severely active ulcerative colitis have been selected for oral presentation as part of the late-breaker session at United European Gastroenterology (UEG) Week 2018.  The presentation will highlight data from the Phase 1b clinical trial of TD-1473 in patients with moderately-to-severely active ulcerative colitis. UEG Week 2018 is being held October 20-24, 2018, in Vienna, Austria.

  • Simply Wall St.13 days ago

    Can Theravance Biopharma Inc (NASDAQ:TBPH) Improve Your Portfolio Returns?

    If you’re interested in Theravance Biopharma Inc (NASDAQ:TBPH), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...

  • Health Care Digest: Upsized record IPO, e-cigarette questions, a CEO Dance and more
    American City Business Journals14 days ago

    Health Care Digest: Upsized record IPO, e-cigarette questions, a CEO Dance and more

    Our weekly Health Care Digest gets your week off to a newsy start with Allogene's upsized IPO, a fresh round of capital for an East Bay ag-bio, a new CEO at an inhaled insulin developer and marketing questions for a San Francisco e-cigarette maker.

  • PR Newswire14 days ago

    Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that data from studies of YUPELRI™ (revefenacin) will be presented at the 2018 CHEST annual meeting, being held in San Antonio, Texas on October 6-10, 2018. Researchers will also report data from a new study comparing outcomes for YUPELRI and tiotropium (Spiriva® HandiHaler®) in COPD patients with suboptimal peak inspiratory flow rates (PIFR). YUPELRI is an investigational long-acting muscarinic antagonist (LAMA) currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of COPD.

  • See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
    Markit14 days ago

    See what the IHS Markit Score report has to say about Theravance Biopharma Inc.

    Short interest is moderately high for TBPH with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • PR Newswire14 days ago

    Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2018

    DUBLIN, Oct. 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that positive new data from multiple studies of VIBATIV® (telavancin) were presented at IDWeek™ 2018, which was held in San Francisco, CA, on October 3 – 7, 2018. Two presentations were made reporting new data from the ongoing Telavancin Observational Use Registry (TOUR™) study, which is designed to report how VIBATIV® (telavancin) is being used by healthcare practitioners to treat patients in real-world clinical settings.

  • TheStreet.com15 days ago

    3 Small Biotech Stocks to Watch in the Fourth Quarter

    The S&P 500 had a good summer. The widely followed index rose more than 7% in the third quarter. It was the best quarterly performance for the S&P 500 since 2013. Profits among S&P 500 companies grew some 25% year over year in the first half of 2018 bolstered by robust domestic economic activity and a big drop in the corporate income tax rate.

  • PR Newswire21 days ago

    Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2018

    Data from TOUR™ Patient Registry Highlight Positive Clinical Response Rates in Patients with Monomicrobial Staphylococcus aureus Infections with Vancomycin MIC ≥ 1 µg/mL Additional TOUR Data Focus on Renal ...

  • Theravance Up as CHMP Backs Trelegy Elipta Line Extension
    Zacks26 days ago

    Theravance Up as CHMP Backs Trelegy Elipta Line Extension

    Theravance Biopharma (TBPH) highlights positive CHMP opinion supporting label expansion of Glaxo's COPD drug, Trelegy Elipta. Theravance has economic interest in the drug and earns royalties on its sales.

  • PR Newswire27 days ago

    Theravance Biopharma to Present at the 2018 Cantor Global Healthcare Conference

    DUBLIN, Sept. 25, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that members of management will present a corporate overview at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 1:40 p.m. ET.  The conference will be held from October 1 - 3 at the Intercontinental Barclay Hotel in New York. A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

  • PR Newswire28 days ago

    Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe

    DUBLIN, Sept. 24, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion supporting the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') in a broader group of patients with moderate to severe chronic obstructive pulmonary disease (COPD) and that labelling, if approved, will be updated to further reflect its effect on exacerbations of COPD. Trelegy Ellipta is the triple combination therapy of FF/UMEC/VI in a single ELLIPTA® inhaler.

  • Theravance, Mylan Report Positive Data on COPD Drug Yupelri
    Zackslast month

    Theravance, Mylan Report Positive Data on COPD Drug Yupelri

    Theravance (TBPH) and partner Mylan post positive data from a late-stage program on COPD Drug, Yupelri.

  • PR Newswirelast month

    Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data from the companies' Phase 3 clinical program for YUPELRI™ (revefenacin) inhalation solution were featured in an oral presentation at the European Respiratory Society (ERS) International Congress 2018, which is being held in Paris, France on September 15-19, 2018. Presented data showed reductions in the rates of chronic obstructive pulmonary disease (COPD) exacerbations ranging from 15% to 18% in moderate to very severe COPD patients administered once-daily YUPELRI for up to 52 weeks as compared to placebo and tiotropium (Spiriva® HandiHaler®). While the YUPELRI Phase 3 program was not designed or powered to achieve statistical significance on differences in COPD exacerbation rates, researchers were interested in a post-hoc analysis of data from the studies to identify trends in this area.

  • See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Theravance Biopharma Inc.

    Theravance Biopharma Inc NASDAQ NMS:TBPH

  • PR Newswirelast month

    Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that new data from the Phase 3 YUPELRI™ (revefenacin) inhalation solution clinical program will be featured in an oral presentation at the European Respiratory Society (ERS) International Congress 2018, being held in Paris, France on September 15-19, 2018. The presented data will highlight chronic obstructive pulmonary disease (COPD) exacerbation rates observed in the Phase 3 clinical program of YUPELRI in patients with moderate to very severe COPD.

  • Theravance Bio (TBPH) Up 2.6% Since Last Earnings Report: Can It Continue?
    Zacks2 months ago

    Theravance Bio (TBPH) Up 2.6% Since Last Earnings Report: Can It Continue?

    Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Theravance Biopharma Inc.

    Short interest is moderately high for TBPH with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Theravance Biopharma (TBPH) Q2 Loss Narrows, Shares Up
    Zacks3 months ago

    Theravance Biopharma (TBPH) Q2 Loss Narrows, Shares Up

    Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q2. Sales beat estimates.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of TBPH earnings conference call or presentation 1-Aug-18 12:00pm GMT

    Q2 2018 Theravance Biopharma Inc Earnings Call

  • Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

    Theravance Bio (TBPH) delivered earnings and revenue surprises of 38.71% and 135.40%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Theravance Bio: 2Q Earnings Snapshot

    The George Town, Cayman Islands-based company said it had a loss of 76 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...